Overview

Study of TRAVATAN in Subjects With Iris Pigmentation Changes

Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN.
Details
Lead Sponsor:
Alcon Research
Treatments:
Ophthalmic Solutions
Travoprost